Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -5.10
- Piotroski Score 4.00
- Grade Buy
- Symbol (VERU)
- Company Veru Inc.
- Price $0.77
- Changes Percentage (-0.38%)
- Change -$0
- Day Low $0.74
- Day High $0.77
- Year High $1.92
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
- Last Earnings 03/24/2014
- Ex-Dividend for 5/16 Dividend 04/28/2014
- Dividend Payable 05/07/2014
- Today N/A
- Next Earnings (Estimated) 12/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $4.00
- High Stock Price Target $5.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.35
- Trailing P/E Ratio -2.62
- Forward P/E Ratio -2.62
- P/E Growth -2.62
- Net Income $-93,088,953
Income Statement
Quarterly
Annual
Latest News of VERU
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Miami father, 9-year-old son killed after Waverunner slams into concrete seawall in Keys
A 47-year-old man and his son tragically died in a watercraft crash in Florida. The man and his son were on a 2018 Yamaha watercraft that collided with a seawall at high speed....
By USA Today | 1 month ago -
Adverum Biotechnologies Shares Rise As Eye Disease Treatment Study Advances
Adverum Biotechnologies announced its therapy for wet age-related macular degeneration was chosen for a late-stage study, causing a rise in its shares. The promising mid-stage results showed a favorab...
By MarketWatch | 2 months ago -
Veru (NASDAQ:VERU) investors are sitting on a loss of 89% if they invested three years ago
Despite a recent 13% increase in Veru Inc. (NASDAQ:VERU) share price, it has faced an 89% drop in the last three years. The company's revenue has also declined significantly, indicating potential chal...
By Yahoo! Finance | 3 months ago
